BioPlus Co., Ltd: debt-to-equity, ROE and more
KOSDAQ, Legal name BioPlus Co., Ltd
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 46.2%
- Equity ratio
- 68.4%
- ROE
- 10.3%
- Op. margin
- 16.5%
- Rev. growth
- 36.9%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩70 | 28.7% |
| 2024 | ₩50 | 20.6% |
| 2023 | ₩70 | 16.4% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 9.9% | 91.0% | 13.3% | 48.7% | n/a |
| FY2022 consolidated | 27.5% | 78.5% | 18.0% | 44.6% | 51.6% |
| FY2023 consolidated | 25.2% | 79.9% | 19.9% | 43.1% | 14.7% |
| FY2024 consolidated | 78.9% | 55.9% | 11.9% | 35.6% | 2.1% |
| FY2025 consolidated | 46.2% | 68.4% | 10.3% | 16.5% | 36.9% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩37.4B | ₩56.7B | ₩65.0B | ₩66.4B | ₩90.9B |
| Operating profit | ₩18.2B | ₩25.3B | ₩28.0B | ₩23.7B | ₩15.0B |
| Pre-tax income | ₩14.2B | ₩27.5B | ₩32.7B | ₩17.7B | ₩17.5B |
| Net income | ₩10.7B | ₩20.7B | ₩27.4B | ₩17.5B | ₩20.0B |
| Total assets | ₩88.5B | ₩146.5B | ₩172.8B | ₩264.3B | ₩285.0B |
| Total liabilities | ₩7.9B | ₩31.6B | ₩34.7B | ₩116.6B | ₩90.1B |
| Total equity | ₩80.5B | ₩115.0B | ₩138.1B | ₩147.7B | ₩195.0B |
| Paid-in capital | ₩7.2B | ₩29.0B | ₩29.0B | ₩29.1B | ₩30.8B |
| Debt/equity (source value) | 9.9% | 27.5% | 25.2% | 78.9% | 46.2% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2003-05-23
- Listed
- 21/09/27
- Employees
- 187
- Auditor
- 우리회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101112785355
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 바이오플러스Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.